85 related articles for article (PubMed ID: 11925850)
1. [Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced influenza-virus-associated encephalopathy].
Funato T; Kozawa K; Kaku M
Rinsho Byori; 2002 Feb; 50(2):140-5. PubMed ID: 11925850
[TBL] [Abstract][Full Text] [Related]
2. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green.
Hiratsuka M; Agatsuma Y; Mizugaki M
Mol Genet Metab; 1999 Nov; 68(3):357-62. PubMed ID: 10562462
[TBL] [Abstract][Full Text] [Related]
3. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
[TBL] [Abstract][Full Text] [Related]
4. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.
Aithal GP; Day CP; Leathart JB; Daly AK
Pharmacogenetics; 2000 Aug; 10(6):511-8. PubMed ID: 10975605
[TBL] [Abstract][Full Text] [Related]
5. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
Shintani M; Ieiri I; Inoue K; Mamiya K; Ninomiya H; Tashiro N; Higuchi S; Otsubo K
Clin Pharmacol Ther; 2001 Aug; 70(2):175-82. PubMed ID: 11503012
[TBL] [Abstract][Full Text] [Related]
7. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
Margaglione M; Brancaccio V; Ciampa A; Di Minno G
Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
[No Abstract] [Full Text] [Related]
8. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
[TBL] [Abstract][Full Text] [Related]
9. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
Yilmaz N; Erbağci AB; Aynacioğlu AS
Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
[TBL] [Abstract][Full Text] [Related]
11. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
12. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele.
Shimamoto J; Ieiri I; Urae A; Kimura M; Irie S; Kubota T; Chiba K; Ishizaki T; Otsubo K; Higuchi S
Eur J Clin Pharmacol; 2000 Apr; 56(1):65-8. PubMed ID: 10853880
[TBL] [Abstract][Full Text] [Related]
13. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
15. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
[TBL] [Abstract][Full Text] [Related]
16. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin J; Cabili S; Lagziel A; Peretz H
Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
[No Abstract] [Full Text] [Related]
17. Genetic susceptibility to hemorrhagic complications during warfarin therapy.
Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA
Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459
[No Abstract] [Full Text] [Related]
18. Is diclofenac a valuable CYP2C9 probe in humans?
Morin S; Loriot MA; Poirier JM; Tenneze L; Beaune PH; Funck-Brentano C; Jaillon P; Becquemont L
Eur J Clin Pharmacol; 2001; 56(11):793-7. PubMed ID: 11294368
[TBL] [Abstract][Full Text] [Related]
19. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.
Zhou D; Lu Y; Steiner MS; Dalton JT
Antimicrob Agents Chemother; 2000 Oct; 44(10):2659-63. PubMed ID: 10991840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
